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dynamic parameters (heart rate, blood pressure, grade 3 or 4 Killip, left
ventricular ejection fraction (LVEF)). In group 1, predictive factors of mor-
tality were: age, three-vessel or left main coronary artery disease, blood pres-
sure, grade 3 or 4 Killip and LVEF.
 
Conclusion: 
 
Despite recent improvement in the management of STEMI,
incidence of patients requiring CAD for CS is still high, and mortality ele-
vated.
 
(Voir tableau page précédente)
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Background:
 
 The impact of hypoxia on left ventricular (LV) myocardial
contractility remains debated. 
Objectives: We hypothesized that acute hypoxia in healthy people increases
LV twist as a consequence of the cardiovascular adaptation to stress (increased
sympathetic nerve activity). Because hypoxia increases heart rate, we aimed to
control for this change by studying the same subjects under atropine during
normoxia. 
 
Methods:
 
 We studied 21 subjects (mean age: 27 ± 7 years) without med-
ical history. Echocardiography was performed in normoxia and after 30 min-
utes of hypoxia (12% FiO
 
2
 
). Short axis basal and apical views were analyzed
using speckle tracking software. LV twist was defined as the net difference
between the apical and basal rotation. The effect of atropine on LV twist was
tested in the same subjects under normoxia.
 
Results:
 
 As expected, hypoxic breathing decreased arterial saturation in
oxygen below 80% (table). Peak LV twist increased, as did heart rate, LV
ejection fraction (LVEF) and systolic mitral annular velocity. Despite a
decrease in mitral E/A ratio, early diastolic LV untwisting (at 5%, 10% and
15% of diastole) was not significantly modified under hypoxia.
Atropine did not alter peak systolic twist (8.9 ± 3.1˚ versus 10.1 ± 2.6˚,p=0.09,
without and with atropine, respectively), despite an increase in heart rate (from
64 ± 11 to 77 ± 11 beats/min, p=0.0001).
Conclusions: Acute hypoxia increases LV twist as well as other parameters of
LV contractility. This change in LV twist does not result from the chrono-
tropic effect of hypoxia.  
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Purpose:
 
 Contrast-induced nephropathy (CIN) after coronariography has
been associated to increased morbidity and mortality. Patients submitted to
primary angioplasty seem to be at higher risk for CIN development, owing in
part to hemodynamic status. We sought to determine the prevalence, predictors
and prognostic value of CIN occurrence after primary angioplasty.
 
Methods:
 
 A total of 141 patients consecutively submitted to primary
angioplasty and admitted to our coronary unit were reviewed. CIN was defined
as impairment of renal function occurring within 48 hours after administration
of contrast media and manifested by an absolute increase in the serum creati-
nine level of at least 0.5 mg/dl or by a relative increase of at least 25% over
the baseline value (in the absence of another cause). The primary end points
were in-hospital and six-month mortality.
 
Results:
 
 CIN developed in 18.4% of the patients (n=26). Patients with CIN
were older (68 ± 13 vs 61 ± 13 years; p <0.05) and more often had diabetes
mellitus (38.5% vs 15.7%; p <0.05). Although statistical significance was not
reached, there was a trend for higher prevalence of hypertension (61.5% vs
42.6%; p=0.09), female gender (30.8% vs 18.3%; p=0.18) and Killip class
higher than one at admission (26.9% vs 16.3%; p=0.1) among patients with
CIN. Patients with CIN had an higher mean time from symptoms to reperfu-
sion (304 ± 192 vs 397 ± 206 minutes; p <0.04). By multivariate analysis,
independent correlates of CIN were older age (OR=1.04; 95%CI=1.01 – 1.08)
and diabetes mellitus (OR=2.99; 95%CI=1.08 – 8.3). Patients with CIN had
higher in-hospital (19.2% vs 0.9%; p <0.05) and 6-month mortality (28.6% vs
4.9%; p <0.05).
 
Conclusions:
 
 CIN was a frequent complication of primary angioplasty
(18.4% of the patients). Independent predictors of CIN after primary angio-
plasty were older age and diabetes mellitus. Patients with CIN had a worse
prognosis, both during in-hospital stay and at 6 months. 
 
333
 
Use of recombinant factor VIIa (NovoSeven) in patients treated with
fondaparinux for ongoing life-threatening bleeding
 
Francois Schiele (1), Paul Luporsi (1), Nicolas Meneveau (1), Evelyne
Racadot (2), Vincent Descotes-Genon (1), Romain Chopard (1), Marie-
France Seronde (1), Sebastien Janin (1)
(1) CHU de Besançon, Cardiologie, Besançon, France - (2) EFS Bourgo-
gne-Franche Comte, Besançon, France
Background:
 
 Recombinant factor VIIa (rFVIIa) may be used to reverse
the anticoagulant effect of fondaparinux. We report a single centre experience
in 8 patients with severe bleeding. 
Methods: Patients pretreated with fondaparinux, with life-threatening
bleeding were treated with 90µg/kg rFVIIa. Life-threatening bleeding was
defined as TIMI 3 bleeding or a drop in hemoglobin > 5g or hemodynamic
shock and elevated antiXa activity. Endpoints were (1) death (2) persistent
bleeding (clinical or continued drop of hemoglobin) (3) uncontrolled hemody-
namic shock (4) clinical arterial or venous thrombosis and (5) peak of
thrombin generation. 
 
Results:
 
 Between June 2008 and November 2009, among 1224 patients
treated with fondaparinux, 8 presented with life-threatening bleeding (3 with
venous thrombo-embolic disease, 5 acute coronary syndrome (ACS)). Patients
with ACS had double (n=2) or triple (n=3) antiplatelet therapy. Bleedings
were related to vascular access in 5, gastro-duodenal in 2 and lung in 1. Five
patients had hemorrhagic shock, mean drop in hemoglobin was 6.1 g/dL. Anti-
Xa activity ranged from 0.67 to 1.62, rFVIIa dose ranged from 3.6 to 7.65mg.
One patient died from uncontrolled shock, no patient had signs of persistent
bleeding or thrombotic complication. In patients with the highest basal anti-Xa
activity (1.14 to 1.62), the time to peak of thrombin generation remained low.
 
  Values are means (SD)
 
 Normoxia Hypoxia p value
SaO
 
2 
 
(%)
 
97 (1.3) 76 (7.8) 0.0001
 
Heart rate (beats/min)
 
64 (11) 70 (9) 0.008
 
LVEF (%)
 
65 (5) 68 (7) 0.011
 
Systolic mitral annular velocity 
(cm/s)
 
8 .0 (1.1) 8.7 (1.4) 0.03
 
E/A 
 
2.1 (0.6) 1.8 (0.4) 0.015
 
Peak LV twist (˚)
 
8.9 (3.1) 11.1(2.8) 0.003
